Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Insulin detemir + Insulin Insulatard refers to a combination or comparative regimen of two basal insulin products: insulin detemir (a long-acting analogue) and Insulin Insulatard (an intermediate-acting NPH human insulin). Insulin detemir, marketed as Levemir, utilizes a fatty acid chain to bind to albumin, resulting in slow absorption and a prolonged duration of action. Insulin Insulatard is a suspension of human insulin with protamine and zinc. This specific combination was evaluated in a Phase 4 randomized crossover trial (NCT00742976) to determine if switching from NPH insulin to insulin detemir affects renal sodium handling, extracellular volume, and body weight in patients with type 2 diabetes mellitus. The study found that insulin detemir was associated with significant weight loss compared to NPH insulin, potentially due to reduced renal sodium retention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on insulin detemir + insulin isophane.